mAbs and antibody variants
Monoclonal antibodies (mAbs) treat many diseases and disorders. Antibody-based therapies have evolved over time to include other types – such as bispecifics, fragments, and conjugates.
mRNA technology has proven itself a flexible and versatile route for prophylactic vaccines. It also holds great promise for therapies and personalized cancer vaccines.
Oligonucleotide therapeutics are based on short, synthetic strands of DNA or RNA that prevent gene expression or hinder protein function by binding to a target gene or protein sequence.
Many gene therapy applications use plasmids and viral vectors to introduce and deliver genetic changes. Develop and manufacture both with proven equipment and support – from start to finish.
Vaccines based on novel molecules like mRNA and viral vectors are on the rise. Increase the opportunity to meet tomorrow’s vaccine manufacturing needs with innovative technologies and process strategies.